将钌-106（106Ru）斑块近距离放射疗法作为静脉化疗后视网膜母细胞瘤的挽救疗法。

IF 1.7 4区医学 Q4 ONCOLOGY

Brachytherapy Pub Date : 2025-01-01 DOI:10.1016/j.brachy.2024.06.008

Vijay Anand Reddy Palkonda , Aiswarya Ramachandran , Bolajoko Abidemi Adewara , Ritesh Verma , Vishal Raval , Swathi Kaliki

{"title":"将钌-106（106Ru）斑块近距离放射疗法作为静脉化疗后视网膜母细胞瘤的挽救疗法。","authors":"Vijay Anand Reddy Palkonda , Aiswarya Ramachandran , Bolajoko Abidemi Adewara , Ritesh Verma , Vishal Raval , Swathi Kaliki","doi":"10.1016/j.brachy.2024.06.008","DOIUrl":null,"url":null,"abstract":"<div><h3>PURPOSE</h3><div>To describe the clinical presentation and treatment outcomes of patients undergoing Ruthenium-106 (<sup>106</sup>Ru) plaque brachytherapy as salvage treatment for retinoblastoma (RB) following intravenous chemotherapy (IVC).</div></div><div><h3>METHODS</h3><div>Retrospective chart review of 44 eyes of 42 patients. The indications for plaque brachytherapy included solid tumor recurrence (n=20; 45%), solid tumor residual (n=16; 36%), new subretinal seeds (n=5; 12%), and new solid tumor (n=3; 7%).</div></div><div><h3>RESULTS</h3><div>The median age at the presentation was 12 months (range, 3–72 months). Based on ICRB classification, 8 (18%), 8 (18%), 16 (36%), and 5 (12%) tumors belonged to Groups B, C, D, and E, respectively. A median interval of 5 months (range 3–21 months) was noted between the last IVC cycle and plaque brachytherapy. The mean tumor height was four mm (range, 1.5–6 mm). All patients were treated with <sup>106</sup>Ru plaque (round or notch) with a median total dose of 45 Gy (range, 40–55 Gy) delivered to the tumor apex. At a mean post plaque follow-up period of 28 months (median, 23 months; range, 3–132 months), tumor completely regressed in 25 eyes (56%). Tumor recurrence within the plaque site was noted in eight eyes (18%) associated with a type 2 regression pattern (75%). At the last follow-up, the globe salvage rate was 24 eyes (55%), while 2 patients (5%) died due to metastasis.</div></div><div><h3>CONCLUSION</h3><div><sup>106</sup>RU plaque brachytherapy can be a useful salvage treatment for focal tumors (new or recurrent) following systemic IVC.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":"24 1","pages":"Pages 76-85"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ruthenium-106 (106Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy\",\"authors\":\"Vijay Anand Reddy Palkonda , Aiswarya Ramachandran , Bolajoko Abidemi Adewara , Ritesh Verma , Vishal Raval , Swathi Kaliki\",\"doi\":\"10.1016/j.brachy.2024.06.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>PURPOSE</h3><div>To describe the clinical presentation and treatment outcomes of patients undergoing Ruthenium-106 (<sup>106</sup>Ru) plaque brachytherapy as salvage treatment for retinoblastoma (RB) following intravenous chemotherapy (IVC).</div></div><div><h3>METHODS</h3><div>Retrospective chart review of 44 eyes of 42 patients. The indications for plaque brachytherapy included solid tumor recurrence (n=20; 45%), solid tumor residual (n=16; 36%), new subretinal seeds (n=5; 12%), and new solid tumor (n=3; 7%).</div></div><div><h3>RESULTS</h3><div>The median age at the presentation was 12 months (range, 3–72 months). Based on ICRB classification, 8 (18%), 8 (18%), 16 (36%), and 5 (12%) tumors belonged to Groups B, C, D, and E, respectively. A median interval of 5 months (range 3–21 months) was noted between the last IVC cycle and plaque brachytherapy. The mean tumor height was four mm (range, 1.5–6 mm). All patients were treated with <sup>106</sup>Ru plaque (round or notch) with a median total dose of 45 Gy (range, 40–55 Gy) delivered to the tumor apex. At a mean post plaque follow-up period of 28 months (median, 23 months; range, 3–132 months), tumor completely regressed in 25 eyes (56%). Tumor recurrence within the plaque site was noted in eight eyes (18%) associated with a type 2 regression pattern (75%). At the last follow-up, the globe salvage rate was 24 eyes (55%), while 2 patients (5%) died due to metastasis.</div></div><div><h3>CONCLUSION</h3><div><sup>106</sup>RU plaque brachytherapy can be a useful salvage treatment for focal tumors (new or recurrent) following systemic IVC.</div></div>\",\"PeriodicalId\":55334,\"journal\":{\"name\":\"Brachytherapy\",\"volume\":\"24 1\",\"pages\":\"Pages 76-85\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brachytherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1538472124001065\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538472124001065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：描述静脉化疗（IVC）后接受钌-106（106Ru）斑块近距离放射治疗作为视网膜母细胞瘤（RB）挽救治疗的患者的临床表现和治疗结果：方法：对42名患者的44只眼睛进行回顾性病历审查。斑块近距离治疗的适应症包括实体瘤复发（20 例；45%）、实体瘤残留（16 例；36%）、新的视网膜下种子（5 例；12%）和新的实体瘤（3 例；7%）：患者发病时的中位年龄为12个月（3-72个月）。根据ICRB分类，分别有8例（18%）、8例（18%）、16例（36%）和5例（12%）肿瘤属于B、C、D和E组。最后一次IVC周期与斑块近距离治疗之间的中位间隔为5个月（3-21个月）。肿瘤平均高度为 4 毫米（范围为 1.5-6 毫米）。所有患者都接受了106Ru斑块（圆形或凹槽形）治疗，肿瘤顶点的中位总剂量为45 Gy（范围为40-55 Gy）。斑块术后平均随访 28 个月（中位数为 23 个月；范围为 3-132 个月），25 只眼睛（56%）的肿瘤完全消退。8只眼睛（18%）的肿瘤在斑块部位复发，并伴有2型消退模式（75%）。结论：106RU斑块近距离放射治疗是治疗全身性IVC术后局灶性肿瘤（新发或复发）的有效救治方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ruthenium-106 (106Ru) plaque brachytherapy as salvage treatment for retinoblastoma following intravenous chemotherapy

PURPOSE

To describe the clinical presentation and treatment outcomes of patients undergoing Ruthenium-106 (¹⁰⁶Ru) plaque brachytherapy as salvage treatment for retinoblastoma (RB) following intravenous chemotherapy (IVC).

METHODS

Retrospective chart review of 44 eyes of 42 patients. The indications for plaque brachytherapy included solid tumor recurrence (n=20; 45%), solid tumor residual (n=16; 36%), new subretinal seeds (n=5; 12%), and new solid tumor (n=3; 7%).

RESULTS

The median age at the presentation was 12 months (range, 3–72 months). Based on ICRB classification, 8 (18%), 8 (18%), 16 (36%), and 5 (12%) tumors belonged to Groups B, C, D, and E, respectively. A median interval of 5 months (range 3–21 months) was noted between the last IVC cycle and plaque brachytherapy. The mean tumor height was four mm (range, 1.5–6 mm). All patients were treated with ¹⁰⁶Ru plaque (round or notch) with a median total dose of 45 Gy (range, 40–55 Gy) delivered to the tumor apex. At a mean post plaque follow-up period of 28 months (median, 23 months; range, 3–132 months), tumor completely regressed in 25 eyes (56%). Tumor recurrence within the plaque site was noted in eight eyes (18%) associated with a type 2 regression pattern (75%). At the last follow-up, the globe salvage rate was 24 eyes (55%), while 2 patients (5%) died due to metastasis.

CONCLUSION

¹⁰⁶RU plaque brachytherapy can be a useful salvage treatment for focal tumors (new or recurrent) following systemic IVC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Brachytherapy 医学-核医学

CiteScore

3.40

自引率

21.10%

发文量

119

审稿时长

9.1 weeks

期刊介绍： Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial and intracavitary radiation in the management of cancers. Laboratory and experimental research relevant to clinical practice is also included. Related disciplines include medical physics, medical oncology, and radiation oncology and radiology. Brachytherapy publishes technical advances, original articles, reviews, and point/counterpoint on controversial issues. Original articles that address any aspect of brachytherapy are invited. Letters to the Editor-in-Chief are encouraged.